Article

A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case.

Division of Head and Neck, Cancer Institute Hospital, Tokyo 135-8550, Japan.
Endocrine Journal (impact factor: 2.03). 09/2007; 54(4):531-5. pp.531-5
Source: PubMed

ABSTRACT Since the majority of multiple endocrine neoplasia type 2A (MEN 2A) patients have missense mutations at codon 634 and those with the Cys630 RET genotype mutations are extremely rare, limited clinical information is available about this rare type. We report here three members of one Japanese MEN 2A family with the Cys630Tyr genotype. A 67-year-old woman presented a firm thyroid nodule, and preoperative examination revealed medullary thyroid carcinoma with primary hyperparthyoidism and no pheochromocytoma. At surgery, bilateral medullary thyroid carcinomas and parathyroid adenoma were found. No lymph node metastasis was identified. Computed tomography scans and laboratory examination of blood have shown no evidence of tumor recurrence and no abnormality of parathyroid function during the 4 years after surgery. A 40-year-old man, the proband's son, was shown to have the same RET mutation, underwent total thyroidectomy prophylactically, and only microscopic foci of medullary thyroid carcinoma were found. A 10-year-old boy, the proband's grandson also having the same RET mutation, showed normal basal serum calcitonin level and has been followed up conservatively. To our knowledge, 18 patients of 6 families with the Cys630 mutations have been reported so far. This is only the second reported case with primary hyperparathyroidism. RET 630 mutations might be associated with lower penetrance of primary hyperparthyoidism and pheochromocytoma.

0 0
 · 
0 Bookmarks
 · 
58 Views
  • Source
    Article: Medullary thyroid cancer: management guidelines of the American Thyroid Association.
    [show abstract] [hide abstract]
    ABSTRACT: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians. Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality. Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including RET oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research. One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.
    Thyroid: official journal of the American Thyroid Association 07/2009; 19(6):565-612. · 2.60 Impact Factor

Keywords

18 patients
 
4 years
 
bilateral medullary thyroid carcinomas
 
Computed tomography scans
 
Cys630 mutations
 
Cys630 RET genotype mutations
 
Cys630Tyr genotype
 
Japanese MEN 2A family
 
limited clinical information
 
lower penetrance
 
lymph node metastasis
 
medullary thyroid carcinoma
 
MEN 2A
 
multiple endocrine neoplasia type 2A
 
normal basal serum calcitonin level
 
parathyroid adenoma
 
primary hyperparthyoidism
 
proband's grandson
 
RET 630 mutations
 
total thyroidectomy prophylactically